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peritoneal carcinomatosis from 14% in the S-arm to 4% in the CRT+S-
arm (p<0.0001). There was also a small, but significant effect on 
hematogenous dissemination in favor of the CRT group (35 vs. 29%, 
p=0.025). LRRs occurred in 5% within the radiation field, in 2% in the 
margins of the radiation field, and in 6% outside the radiation field 
while in 1% the exact site in relation to the radiation field was 
unclear. Only 1% of patients had an isolated infield LRR after CRT+S. 
Conclusions: In patients with esophageal or junctional cancer, 
preoperative chemoradiotherapy improves locoregional control, 
reduces peritoneal carcinomatosis and has a favorable effect on 
hematogenous dissemination. Infield locoregional recurrences are 
rare.  
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Purpose/Objective: To evaluate the feasibility of high-dose 
stereotactic body radiation therapy (SBRT) in the treatment of 
unresectable liver metastases. 
Materials and Methods: Patients with one to three unresectable liver 
metastases with maximum individual tumour diameters less than 6cm, 
a Karnofsky Performance Status of at least 70, were enrolled and 
treated by SBRT on a phase II clinical trial. Dose prescription was 75Gy 
in 3 consecutive days.. SBRT was delivered using the volumetric 
modulated arc therapy (VMAT) by RapidArc technique, The primary 
end point was in–field local control. Secondary end points were 
toxicity, and survival. 
Results: Between February 2010 and September 2011, 61 patients 
with 76 lesions were treated. Among them, 21 (34.3%) had stable 
extrahepatic disease at study entry. The most frequent primary sites 
were colorectal(45.9%) and breast cancer(18%). 78.7% of patients had 
one lesion, 18.0% and 3.3% had 2 and 3 lesions, respectively. After a 
median of 12 months (range 2-26 months) in–field local response rate 
was 94%. Median OS rate was 19 months, actuarial survival at 12 
months was 83.5%. None of the patients suffered from grade 3 or 
higher acute toxicity. No radiation induced liver disease (RILD) was 
detected. One patient experienced G3 late toxicity at 6 months, due 
to chest wall pain. 
Conclusions: SBRT for unresectable liver metastases can be 
considered as an effective, safe, and noninvasive therapeutic option 
with excellent rates of local control and a low treatment related 
toxicity.  
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Purpose/Objective: During the ACCORD12 randomized trial, a specific 
evaluation of the clinical tumor response of the rectal cancer 
following neoadjuvant chemoradiotherapy (CRT) was performed 
before surgery. The correlation of this end point with patient 
characteristics and treatment outcomes is reported. 
Materials and Methods: Between 2005 and 2008 a randomized trial 
comparing 2 different regimens of CRT (cap45 : capecitabine + 45 
Gy/5w vs capox50 : capecitabine + 50 Gy/5w + oxaliplatine) included 
598 patients. A careful evaluation of the clinical response of the 
tumor was planned 5 weeks after the end of CRT just before surgery. 
Rectoscopy and digital rectal examination (DRE) was used to establish 
a specific score of clinical response adapted from the RECIST criteria : 
Clinical complete response : no visible or palpable tumor, supple 
rectal wall (CCR) ; partial response (PR), stable disease (ST), 
progressive disease (PROG). This score was correlated with patients 
characteristics, type of surgery, pathological response and 3-year 
clinical outcome. 
Results: Clinical response was evaluable in 475 patients. Score was as 
follow : CCR : 5%, PR : 62%, ST : 29%, PROG : 4%. There was a trend 
toward more CCR in the capox 50 arm (6,5 % vs 3,7 %). When analysed 
for the whole cohort of 475 patients, CCR was associated with early T 
stage (T2 : 11% vs T3-4 : 5%). CCR was associated with sphincter 
saving surgery, ypCR, CRM+, Disease Free Survival (table 1). 
Conclusions: CCR appears as a very important end point after 
neoadjuvant treatment of rectal cancer. It is correlated with 
increased pCR, negative CRM, 3 year DFS and it is probably influencing 
the chance of a sphincter saving procedure. Rectoscopy and DRE 
should be performed after neoadjuvant CRT to evaluate the tumor 
response and adapt the surgical technique.  
Reference : JP Gérard et al. Clinical outcome ACCORD12. 
10.1200/JCO.2012.42.8771 
 
 CCR (24 pts) % Part;Stable;Prog (451 pts) % 
Sph. Sav. Surg. 21 88 % 380 71 % 
ypCR 14 58 % 72 16 % 
CRM+ (≤1mm) 0 0 % 45 10 % 
3y DFS 91 % 70 % 
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Purpose/Objective: The increased use of high conformal radiation 
techniques with steep dose gradients requires a very precise definition 
of the clinical target volume (CTV). Although delineation guidelines 
are widely available, little is known about their correct 
implementation into daily practice. Within a national project we 
investigated the impact of central review on the quality of CTV 
delineation based on the guidelines as published by Roels et al 
(IJROBP 2006). 
Materials and Methods: Dedicated software (Aquilab, France) was 
installed at a central review facility and at each participating 
radiation oncology department. The CTV was uploaded on a secured 
server and centrally reviewed. In order to account for the variability 
in the time of inclusion between two patients in and between centres, 
we used a ranking system in which each 5 consecutive patients per 
centre were regarded as one category. This categorical patient order 
(cpatorder) was correlated with three volumetric parameters: kappa 
index (KI), volumetric ratio (RV) and commonly contoured volume 
(VCC). To compare the results of the volumetric parameters between 
the first ten patients and the others per centre a sensitive analysis 
was performed. A generalized linear model was used for normally 
distributed parameters (RV) and a regression logistic model for non-
normally distributed parameters (KI, VCC).  
Results: Between March 2010 and September 2012, 20 centres 
submitted 1255 rectal cancer cases, from which 1224 were included in 
the final analysis. A median of 64 patients were submitted per centre 
(range 6 -198). CTV was modified in 74.2% of the cases. Sensitive 
analysis demonstrated that there was a significant increase in RV and 
VCC between the first ten patients and the others (p<0.0005 resp. 
p<0.05) (Fig. 1). Statistical analysis did not show a sustained 
significant improvement in CTV delineation during the whole review 
period. When assessing the influence of the location of the primary 
tumour on CTV delineation, there was less consensus on delineation 
for mid seated lesions compared to low and high seated tumours. This 
might be explained by disagreement on which nodal volumes to 
include. 
 
